282 related articles for article (PubMed ID: 8732453)
1. The change in 123I-uptake between 3- and 24-hours is useful in predicting early response to methimazole in patients with Graves' disease.
Gemma R; Nakamura H; Mori T; Andoh S; Suzuki Y; Yoshimi T
Endocr J; 1996 Feb; 43(1):61-6. PubMed ID: 8732453
[TBL] [Abstract][Full Text] [Related]
2. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine uptake after monotherapy with potassium iodide in patients with Graves' disease.
Mikura K; Yoshimura Noh J; Watanabe N; Aida A; Yoshimura R; Kinoshita A; Suzuki A; Suzuki N; Fukushita M; Matsumoto M; Yoshihara A; Sugino K; Ito K
Endocr J; 2023 May; 70(5):541-549. PubMed ID: 36843112
[TBL] [Abstract][Full Text] [Related]
4. Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease.
Tada H; Mizuta I; Takano T; Tatsumi KI; Izumi Y; Hidaka Y; Amino N
Clin Endocrinol (Oxf); 2003 Apr; 58(4):403-8. PubMed ID: 12641621
[TBL] [Abstract][Full Text] [Related]
5. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
[TBL] [Abstract][Full Text] [Related]
6. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
7. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
[TBL] [Abstract][Full Text] [Related]
8. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
Reinwein D; Benker G; Lazarus JH; Alexander WD
J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
[TBL] [Abstract][Full Text] [Related]
10. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
11. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
Werner RS; Romaldini JH; Farah CS; Werner MC; Bromberg N
Thyroid; 1991; 1(4):293-9. PubMed ID: 1688155
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
[TBL] [Abstract][Full Text] [Related]
13. Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism.
Horn-Lodewyk J
Endocr J; 2019 Dec; 66(12):1047-1052. PubMed ID: 31391354
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
15. Re-establishment of normal radioactive iodine uptake reference range in the era of universal salt iodization in the Indian population.
Ballal S; Soundararajan R; Bal C
Indian J Med Res; 2017 Mar; 145(3):358-364. PubMed ID: 28749399
[TBL] [Abstract][Full Text] [Related]
16. Prediction of late (24-hour) radioactive iodine uptake using early (3-hour) uptake values in Japanese patients with Graves' disease.
Osaki Y; Sakurai K; Arihara Z; Hata M; Fukazawa H
Endocr J; 2012; 59(2):173-7. PubMed ID: 22095001
[TBL] [Abstract][Full Text] [Related]
17. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
[TBL] [Abstract][Full Text] [Related]
18. Response to methimazole in Graves' disease. The European Multicenter Study Group.
Benker G; Vitti P; Kahaly G; Raue F; Tegler L; Hirche H; Reinwein D
Clin Endocrinol (Oxf); 1995 Sep; 43(3):257-63. PubMed ID: 7586593
[TBL] [Abstract][Full Text] [Related]
19. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
[TBL] [Abstract][Full Text] [Related]
20. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
